Nine Escherichia coli and 5 Klebsiella pneumoniae clinical isolates resistant to various cephalosporins and cephamycins were identified in a Japanese general hospital between 1995 and 1997. All nine E. coli isolates and one K. pneumoniae isolate carried bla CMY-9 , while the other four K. pneumoniae isolates harbored a variant of bla CMY-9 , namely, bla CMY-19 . The pulsed-field gel electrophoresis patterns of the nine CMY-9-producing E. coli isolates were almost identical, suggesting their clonal relatedness, while those of the five K. pneumoniae isolates were divergent. Plasmid profiles, Southern hybridization, and conjugation assays revealed that the genes for the CMY-9 and the CMY-19 ␤-lactamases were located on very similar conjugative plasmids in E. coli and K. pneumoniae. The genetic environment of bla CMY-19 was identical to that of bla CMY-9 . A single amino acid substitution, I292S, adjacent to the H-10 helix region was observed between CMY-9 and CMY-19. This substitution was suggested to be responsible for the expansion of the hydrolyzing activity against several broad-spectrum cephalosporins, and this finding was consistent with the kinetic parameters determined with purified enzymes. These findings suggest that the bla CMY-19 genes found in the four K. pneumoniae isolates might have originated from bla CMY-9 gene following a point mutation and dispersed among genetically different K. pneumoniae isolates via a large transferable plasmid.
a 2% agarose gel and purified with a MinElute gel extraction kit (QIAGEN K. K., Tokyo, Japan), and both strands were sequenced.
Transfer of ␤-lactam resistance. A conjugation experiment was performed by the broth mating method with E. coli strain CSH-2 (metB F Ϫ Rif r Nal r ) as the recipient. The donor-to-recipient ratio was 1:4, and the mating time was 3 h. Transconjugants were selected on Luria-Bertani (LB) agar plates supplemented with both rifampin (100 g/ml) and nalidixic acid (50 g/ml), together with cefotaxime (10 g/ml) or ceftazidime (10 g/ml).
Antibiotic susceptibility tests. Susceptibilities to antibiotics were tested by the agar dilution method according to the procedure recommended by the CLSI (formerly the National Committee for Clinical Laboratory Standards) document M7-A5 (24) . E. coli ATCC 25922 was used as the control strain for the antimicrobial susceptibility testing.
Isoelectric focusing of ␤-lactamases. Bacterial cells were grown in 10 ml of LB broth supplemented with cephalothin (50 g/ml) and were harvested by centrifugation (4,000 ϫ g for 15 min) The cell pellet was resuspended in 1 ml of 50 mM sodium phosphate buffer. The pI of ␤-lactamase was determined as described previously (31) .
Pulsed-field gel electrophoresis (PFGE). Total DNA preparations containing both chromosomal and plasmid DNAs were extracted from each isolate and digested overnight with XbaI (New England Biolabs, Beverly, MA) in agarose gel plugs. The digested DNAs were subjected to electrophoresis with a CHEF-DRII drive module (Bio-Rad Laboratory, Hercules, CA), with pulses ranging from 12.5 to 40 s at 6 V/cm for 24 h at 16°C.
Plasmid analysis and Southern hybridization. Large plasmids mediating bla CMY genes were prepared from clinical isolates and their transconjugants according to the procedure described by Kado and Liu (17) and electrophoresed on a 0.8% agarose gel. The plasmid DNAs of the transconjugants were also prepared by using a QIAGEN midi-prep kit (QIAGEN K. K.), digested with SacI, and then transferred to a nylon membrane (Bio-Rad Laboratories). The 999-bp digoxigenin (DIG)-labeled DNA probes were prepared by using a PCR DIG Probe Synthesis kit (Roche Diagnostics, Tokyo, Japan); and the DNA template was prepared from a bla MOX -positive E. coli strain HKYM68 (12) , together with two PCR primers, primers MOX-F (5Ј-AAC AAC GAC AAT CCA TCC-3Ј) and MOX-R (5Ј-TGT TGA AGA GCA CCT GGC-3Ј).
PCR and sequencing analyses of flanking regions of bla CMY . To determine the genetic environments of the bla CMY genes, standard PCR amplification experiments and sequencing analyses were performed with an Expand High-Fidelity PCR system (Roche) and several sets of primers, which were designed on the basis of the nucleotide sequences deposited in the EMBL/GenBank/DDBJ databases under accession number AB061794. The resultant PCR products were purified by using a MinElute gel extraction kit (QIAGEN) and were subsequently sequenced with the appropriate primers.
Cloning of bla CMY-9 and bla CMY-19 for purification of enzymes. To amplify bla CMY-9 and bla , conjugative plasmids pK209 and pK466 were used as the template DNA, respectively. A highly reliable PCR amplification was performed with primers CMY-S1 (5Ј-CAG GGC GTG AGG ATA AAG-3Ј) and CMY-S2 (5Ј-GGG ACG AGA TAG AGA AAT-3Ј) by using the Expand HighFidelity PCR system (Roche). Each amplicon was ligated to the pGEM-T vector (Promega, Madison, WI) and subjected to confirmatory sequencing. Selected plasmids with no amplification error, pGEM-CMY-9 and pGEM-CMY-19, which carry bla CMY-9 and bla , respectively, were digested with XhoI and EcoRI. The resultant fragments were ligated to pBCSKϩ (Stratagene, La Jolla, Calif.) restricted with the same enzymes; and competent cells of E. coli strain DH5␣ [supE44 ⌬lacU169 (80 lacZ⌬M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 acrAB ϩ ], purchased from TOYOBO, Co., Ltd, Tokyo, Japan, were transformed by electroporation with the mixture of the constructed plasmids.
Purification of CMY-9 and CMY-19 ␤-lactamases. E. coli strain DH5␣, which harbored pBC-CMY-9 carrying the bla CMY-9 gene or pBC-CMY-19 carrying the bla CMY-19 gene, was separately cultured overnight in 2 liters of LB broth containing cephalothin (50 g/ml) and chloramphenicol (30 g/ml). The cells were harvested by centrifugation and washed in 50 mM sodium phosphate buffer (pH 7.0). The pellets were resuspended with 10 ml of 20 mM Tris-HCl buffer (pH 7.5) and destroyed with a French press. After low-speed centrifugation (3,300 ϫ g for 15 min) to remove the cellular debris and unbroken cells, the supernatant was again centrifuged at 100,000 ϫ g for 1 h at 4°C. The supernatant containing ␤-lactamase was chromatographed through a HiTrap Q HP column (Amersham Biosciences) that had been preequilibrated with 20 mM Tris-HCl buffer (pH 7.5). ␤-Lactamase activity was detected in the flowthrough fraction, which was then dialyzed against 50 mM sodium phosphate buffer (pH 6.0). This partially purified fraction was again applied to a HiTrap SP HP column (Amersham Biosciences) that had been preequilibrated with 50 mM sodium phosphate buffer (pH 6.0). The enzymes were eluted with a linear gradient of NaCl in the same buffer.
Fractions with ␤-lactamase activity were dialyzed against 50 mM sodium phosphate buffer (pH 7.0) and condensed by use of an Ultrafree-15 centrifuge filter device (Millipore Corporation, Bedford, MA). The production of CMY-19 was not enough in the E. coli transformant, so the following method was used. The bla gene was amplified with primers CMY-F2 (5Ј-CAT ATG CAA CAA CGA CAA TCC ATC C-3Ј), which has an NdeI linker (underlined), and CMY-R2 (5Ј-GAA TTC TCA ACC GGC CAA CTG CGC CA-3Ј), which has an EcoRI linker (underlined), and the Expand High-Fidelity PCR system (Roche). The amplicon was ligated with a pGEM-T vector (Promega), subjected to confirmatory sequencing, and then excised by digestion with NdeI and EcoRI and subcloned into the expression vector pET29a(ϩ) (Novagen, Madison, WI), which was cleaved with the same enzymes. The constructed expression vector, named pET-CMY-19, was introduced into E. coli
, which was obtained from Novagen through TAKARA BIO Inc., Kyoto, Japan. The transformant was cultured in 1 liter of LB broth containing kanamycin (50 g/ml) and chloramphenicol (30 mg/ml) at 37°C. Isopropyl-␤-D-thiogalactopyranoside was added when the culture reached an optical density at 600 nm of 0.55, and the culture was incubated for an additional 6 h at 25°C. CMY-19 was purified by the same methods used for the purification of CMY-9. The purity of the ␤-lactamases was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie brilliant blue (CBB) staining. The purified CMY-9 and CMY-19 ␤-lactamases were also subjected to isoelectric focusing analysis with an Ampholine PAG plate (Amersham Biosciences) and stained with CBB.
Assay of kinetic parameters. The kinetic parameters of CMY-9 and CMY-19 against various ␤-lactam substrates were assayed at 30°C in 50 mM sodium phosphate buffer (pH 7.0) by using an autospectrophotometer (V-550; Nihon Bunko Ltd., Tokyo, Japan). The absorption maxima of the substrates used were as follows: ampicillin, 235 nm; piperacillin, 232 nm; cephalothin, 262 nm; cephaloridine, 297 nm; ceftizoxime, 257 nm; ceftazidime, 274 nm; cefotaxime, 264 nm; cefpirome, 267 nm; cefepime, 275 nm; cefoxitin, 270 nm; cefmetazole, 259 nm; moxalactam, 274 nm; imipenem, 298 nm. K m and k cat values were obtained by a Michaelis-Menten plot of the initial steady-state velocities at different substrate concentrations. K i was determined by the procedure described in our previous study (13) , with cephalothin used as a reporter substrate.
Nucleotide sequence accession number. The open reading frame of bla CMY-19 was deposited in the EMBL/GenBank databases through DDBJ and assigned accession number AB194410.
RESULTS
Properties of nine E. coli and five K. pneumoniae clinical isolates. The MICs of six ␤-lactams for the 14 clinical isolates are shown in Table 1 . The K. pneumoniae and E. coli clinical isolates exhibited resistance to oximino-cephalosporins and cephamycins but were susceptible to carbapenems, although E. coli HKYM68 also showed resistance to imipenem. In a double-disk synergy test, no synergistic effect of clavulanic acid on the activities of ceftazidime and cefotaxime was detectable in any of the 14 isolates. A lack of metallo-␤-lactamase production was also suggested by the results of the sodium mercaptoacetic acid disk tests. An apparent expansion of the growth inhibitory zone was observed with the 14 clinical isolates only between a disk containing 300 g of 3-aminophenyl-boronic acid and a disk containing ceftazidime or cefotaxime, suggesting the production of a class C ␤-lactamase. These findings indicate that the property of resistance to oxyimino-cephalosporins and cephamycins was likely due to the production of a class C ␤-lactamase.
PCR detection of various ␤-lactamase genes and sequencing revealed that a K. pneumoniae isolate (HKY209) carried bla CMY-9 , while the other four K. pneumoniae isolates carried bla , a variant gene of bla (Table 1) . A single nucleotide mutation at position 944 was found between bla CMY-9 and the newly identified bla CMY-19 gene, and this point mutation resulted in the I292S substitution near the H-10 helix domain in CMY-19, as shown in Fig. 1 . All nine E. coli clinical isolates carried both the bla CMY-9 and the bla TEM genes (Table 1) . VOL. 50, 2006 CEFEPIME-HYDROLYZING CLASS C ␤-LACTAMASE CMY-19 535 The mechanism of imipenem resistance of HKYM68 was not characterized in this work. Transferability of ␤-lactam resistance. The oximino-cephalosporin and cephamycin resistance trait of the five K. pneumoniae was transferred to a recipient E. coli strain (strain CSH-2) at a frequency of 10 Ϫ4 to 10 Ϫ5 cells per recipient cell by broth mating. Conjugal transfer of the resistance trait from the nine E. coli isolates was also observed at a frequency of about 10 Ϫ3 to 10 Ϫ4 cells per recipient cell. PCR analyses confirmed the presence of bla CMY-9 or bla in each transconjugant, indicating that these genes are located on transferable plasmids. PCR analysis of the transconjugants also revealed no cotransmission of the bla TEM gene to the E. coli transconjugants that harbored the bla CMY-9 gene.
PFGE analysis. The PFGE patterns of the five K. pneumoniae isolates after XbaI digestion were highly variable ( Fig. 2A) (22) is shown. Square boxes show the amino acid substitutions or deletions that are predicted to affect the hydrolyzing activity of cefepime. The conserved motif KTG is underlined. Dashes indicate deletions of amino acid residues. CMY-11-and FOX-type enzymes have a serine residue at amino acid position 292, but no observation about their property against cefepime was described in the articles. The numbering of the amino acid residues is in reference to that of the mature CMY-1 reported by Bauernfeind et al. (7) revealed their clonal diversity. In contrast, the PFGE patterns of the E. coli isolates were very similar to one another (Fig. 2B) , which revealed their clonal relatedness. Plasmid analyses and Southern hybridization. The plasmid DNA profiles prepared from the five K. pneumoniae isolates and their transconjugants and from two representative E. coli isolates (isolates HKY154 and HKYM68) and their transconjugants are shown in Fig. 3A . One to three large plasmids were apparently present in the five K. pneumoniae isolates, and one large plasmid was transferred to E. coli from each strain in the conjugation experiment. E. coli isolate HKY154 had four plasmids, and identical plasmid profiles were found in seven other E. coli isolates (isolates HKY191, HKY200, HKY215, HKY224, HKY297, HKY315, and HKY334) (data not shown). E. coli HKYM68 harbored three plasmids that were similar to three of the four plasmids found in HKY154. All the E. coli transconjugants carried a single plasmid apparently identical to that transferred from the K. pneumoniae isolates (Fig. 3A and data not  shown) .
A plasmid of similar size hybridized with the DNA probe specific for the CMY-1-type ␤-lactamase genes in all the K. pneumoniae and E. coli isolates and their transconjugants (Fig.  3B) . The SacI restriction profiles of the plasmid DNAs from representative transconjugants were very similar to each other (Fig. 4A) , and the DNA probe specific for bla CMY-1 -group genes hybridized with a band of about 4.8 kb in size in all cases (Fig. 4B) .
Isoelectric focusing of ␤-lactamases. A ␤-lactamase band with a pI of Ͼ8.45 was detected in all K. pneumoniae and E. coli clinical isolates and their transconjugants but not in E. coli CSH-2 (data not shown). This band likely corresponded to the CMY-9 or CMY-19 ␤-lactamase. No band with an acidic pI value was detected in the nine E. coli clinical isolates carrying the bla TEM gene, likely because of a low level of expression of that gene.
Genetic environments of bla CMY-9 and bla CMY-19 genes. The structure of the flanking regions of the bla CMY-9 gene in E. coli HKYM68 was already reported in a previous study (12) . The structure surrounding the bla CMY genes in the other 13 isolates was identical to that found in HKYM68. Both bla CMY-9 and bla were located at the 3Ј end of a putative transposase gene, orf513. A sul1-type class 1 integron structure consisting of intI1 (an integrase gene), a fused aacA1-orfG gene cassette (responsible for aminoglycoside resistance), qacE⌬1, and sul1 (responsible for trimethoprim-sulfamethoxazole resistance) were found at the 5Ј end of orf513 (Fig. 5) . The bla CMY gene on the conjugative plasmid found in the K. pneumoniae and E. coli clinical isolates located just downstream of orf513 is shown as it was found in our previous study on a CMY-9 producing E. coli HKHM68 (12) . Open circle, position of the 59-base element; CS, conserved segment of a class 1 integron. orf513 is speculated to encode a putative transposase, and various antimicrobial resistance genes tend to be integrated just downstream the orf513. The product from the yqgF gene encodes a hypothetical protein very similar to the YqgF identified in Aeromonas hydrophila (EMBL accession no. AJ276030), but the function is unknown.
MICs for CMY-9-or CMY-19-producing E. coli transformants. The MICs of various ␤-lactams for CMY-9-or CMY-19-producing E. coli transformants are shown in Table 2 . Some notable differences were observed between the MICs of the two strains. The MICs of ampicillin and piperacillin for the CMY-19 producer were higher than those for the CMY-9 producer. Concerning ceftizoxime and cefotaxime, the MICs for the CMY-9 producer were higher than those for the CMY-19 producer, but in the case of ceftazidime, the level of resistance was reversed. The CMY-19 producer showed higher levels of resistance to cefpirome and cefepime than the CMY-9 producer. The MICs of cephamycins, such as cefoxitin, cefmetazole, and cefminox, were higher for the CMY-9 producer than for the CMY-19 producer. A remarkable reduction in the MICs by the addition of a class C ␤-lactamase specific inhibitor, 3-aminophenyl boronic acid, was observed with both the CMY-9 and the CMY-19 producers.
Kinetic parameters. To purify the CMY-9 and the CMY-19 ␤-lactamases, initially, E. coli DH5␣(pBC-CMY-9) and E. coli DH5␣(pBC-CMY-19) were cultured in 2 liters of LB broth. However, the yield of purified CMY-19 ␤-lactamase was insufficient for the assay of kinetic parameters. Therefore, a pET29a(ϩ) expression vector and an E. coli BL21(DE3) pLysS strain were used for overproduction and purification of that enzyme. The purified enzymes gave a single band on SDS-PAGE with CBB staining that suggested Ͼ95% purity (data not shown).
The kinetic parameters of CMY-9 and CMY-19 against selected ␤-lactams are shown in Table 3 . The hydrolyzing activity (k cat /K m ) of CMY-19 for penicillins, including ampicillin and piperacillin, were higher than those of CMY-9. Although CMY-9 and CMY-19 had similar k cat values for cefotaxime, CMY-19 had a 100-fold-higher K m than CMY-9, resulting in a lower catalytic efficiency for this substrate. Ceftazidime, cefpirome, and cefepime behaved as poor substrates for CMY-9 due to the high K m values for these agents, while CMY-19 showed different behaviors against these compounds. CMY-19 had a 140-fold-lower K m against ceftazidime than CMY-9. The k cat value of CMY-9 for cefepime could not be determined, but CMY-19 measurably hydrolyzed this compound. The hydrolyzing efficiencies (k cat /K m values) of CMY-19 against cephamycins such as cefoxitin and cefmetazole were lower than those of CMY-9. Although CMY-19 had a lower K m against cephamycins than CMY-9, it showed a much lower k cat against these compounds.
DISCUSSION
A plasmid-mediated class C ␤-lactamase (CMY-1) was first reported in 1989 in a K. pneumoniae isolated in South Korea (8) . Subsequently, several variants of that enzyme, such as MOX-1 (16), CMY-8 (33), CMY-9 (12), , and CMY-11 (21) , have been identified, mainly in East Asian countries, including Taiwan and Japan. The dissemination of CMY- 10-and CMY-11-producing isolates of the family Enterobacteriaceae was also reported in Korea (18, 19) . In the present study, CMY-type ␤-lactamase-producing K. pneumoniae and E. coli clinical isolates from a Japanese general hospital were investigated. Through PFGE analysis, it was found that the five K. pneumoniae isolates had little genetic relatedness to each other, while the nine E. coli isolates belonged to the same clonal lineage. Interestingly, plasmid analysis showed that all 14 isolates harbored a very similar conjugal plasmid that encodes a CMY-type ␤-lactamase which was either CMY-9 or CMY-19, a variant that differs from CMY-9 by a single amino acid substitution (I292S). Since the flanking structures of the bla CMY genes were identical in all plasmids, it is probable that one conjugal plasmid carrying bla CMY-9 was horizontally transferred to E. coli, K. pneumoniae, and then an E. coli clone and various K. pneumoniae strains harboring the bla CMY genebearing plasmids might have spread in the hospital. ␤-Lactamases can modify their substrate specificity through a single amino acid substitution (30) . CMY-19 had a single amino acid substitution, I292S, near the H-10 helix domain, compared with the sequence of CMY-9 ( Fig. 1) . Indeed, a serine residue at the same amino acid position was found in all the FOX-type enzymes (15, 26) , including CAV-1 (14) , and also in CMY-11 (21) , as shown Fig. 1 ; but no peculiar behavior against cefepime was documented with those enzymes. Through the I292S substitution, CMY-19 would have developed extended substrate specificity against cefepime and cefpirome, as well as ampicillin, piperacillin, cephaloridine, and ceftazidime, compared with that of CMY-9, although the hydrolyzing activities against ceftizoxime, cefotaxime, and cephamycins were impaired. The expansion of hydrolyzing activity against cefepime found in CMY-19 was a most remarkable property because cefepime is generally stable against AmpC ␤-lactamases (11). Similar developments of extended hydrolyzing activity against cefepime through amino acid substitutions or deletions adjacent to the H-10 helix have been observed in several chromosomally encoded AmpC ␤-lactamases, such as the AmpC of Serratia marcescens that lacks four amino acids at positions 293 to 296 (22) , an AmpC of E. coli that lacks three amino acids at positions 286 to 288 (13) , an AmpC of Enterobacter cloacae that lacks six amino acids at positions 289 to 294 (6) , and an AmpC of Enteroacter aerogenes that acquired an L293P substitution (5). Furthermore, Barlow and Hall reported on the in vitro selection of CMY-2 ␤-lactamase variants with several amino acid substitutions, including replacements at positions 292, 293, 294, 296, and 298, which demonstrated increased resistance to cefepime (4) . From our previous molecular modeling analyses (13) , it was found that the expansion of an open space in the vicinity of the R-2 side chain of ceftazidime or cefepime through the deletion of tripeptides in the H-10 helix of E. coli AmpC (Fig. 1) played a crucial role in the acquisition of the greater hydrolyzing activity against those agents possessing a bulky R side chain. Although the actual mechanism for the higher cefepime-hydrolyzing activity in CMY-19 compared to that in CMY-9 has not been elucidated, a similar molecular distortion at the active center of the enzyme might well have occurred in CMY-19. This speculation would be substantiated by molecular modeling and X-ray crystallographic analyses.
